Novo Nordisk A/S Says Diabetes Drug Victoza Superior to Merck & Co., Inc.'s Januvia

Published: Apr 09, 2012

BAGSVAERD, DENMARK--(Marketwire - April 06, 2012) - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza® (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to Januvia® (sitagliptin).

Company announcement 22 2012:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Further information:


Mike Rulis
Tel: (+45) 3079 3573
Email Contact


Klaus Bulow Davidsen
Tel: (+45) 4442 3176
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

In North America:
Ambre Morley
Tel: (+1) 609 216-5240
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact

Back to news